HIV-1 protease inhibitors. A review for clinicians

S. G. Deeks, M. Smith, M. Holodniy and J. O. Kahn
University of California, San Francisco, USA.

OBJECTIVE: The clinical care of people infected with human immunodeficiency virus (HIV) has been substantially affected by the introduction of HIV-specific protease inhibitors (PIs). The 4 PIs available are saquinavir mesylate, ritonavir, indinavir sulfate, and nelfinavir mesylate. Comparison studies have not been reported; therefore, an assessment of the available data to aid clinicians and patients in choosing appropriate treatment will be presented. DATA SOURCES: A systematic review of peer-reviewed publications, abstracts from national and international conferences, and product registration information through September 1996. STUDY SELECTION AND DATA EXTRACTION: Criteria used to select studies include their relevance to PIs, having been published in the English language, and pertinence for clinicians. Data quality and validity included the venue of the publication and relevance to clinical care. DATA SYNTHESIS: Oral adminstration of ritonavir, indinavir, or nelfinavir generates sustainable drug serum levels to effectively inhibit the protease enzyme; however, saquinavir may not generate sustained levels necessary to inhibit the protease enzyme. Patients treated with ritonavir, indinavir, or nelfinavir experience similar reductions in viral load and increases in CD4+ lymphocytes; smaller effects occur among those treated with saquinavir. Two randomized placebo-controlled studies conducted among patients with severe immune system suppression and substantial zidovudine treatment experience demonstrated reduced HIV disease progression and reduced mortality with PI treatment. Genotypic resistance to PIs occurs; the clinical relevance of resistance is unclear. The costs of these agents including required monitoring impose new and substantial costs. CONCLUSIONS: The PIs have emerged as critical drugs for people with HIV infection. Optimal use involves combination with reverse transcriptase inhibitors. Resistance develops to each agent, and cross-resistance is likely. These agents must be used at full doses with attention to ensuring patient compliance. The expense of these agents may be offset by forestalling disease progression and death and returning people to productive life. Selecting the initial PI must be individualized, and factors to consider include proven activity, possible toxicities, dosing regimens, drug interactions, and costs.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Comparative Evaluation of the Inhibitory Activities of a Series of Pyrimidinedione Congeners That Inhibit Human Immunodeficiency Virus Types 1 and 2
Buckheit et al.
Antimicrob. Agents Chemother. 2008;52:225-236.
ABSTRACT | FULL TEXT  

Human Immunodeficiency Virus Protease Inhibitor Ritonavir Inhibits Cholesterol Efflux from Human Macrophage-Derived Foam Cells
Wang et al.
Am. J. Pathol. 2007;171:304-314.
ABSTRACT | FULL TEXT  

HIV Protease Inhibitors Enhance the Efficacy of Irradiation
Cuneo et al.
Cancer Res. 2007;67:4886-4893.
ABSTRACT | FULL TEXT  

Evaluation of Antitumoral Properties of the Protease Inhibitor Indinavir in a Murine Model of Hepatocarcinoma
Esposito et al.
Clin. Cancer Res. 2006;12:2634-2639.
ABSTRACT | FULL TEXT  

HIV Protease Inhibitors Block Akt Signaling and Radiosensitize Tumor Cells Both In vitro and In vivo
Gupta et al.
Cancer Res. 2005;65:8256-8265.
ABSTRACT | FULL TEXT  

Highly Potent Inhibition of Human Immunodeficiency Virus Type 1 Replication by TAK-220, an Orally Bioavailable Small-Molecule CCR5 Antagonist
Takashima et al.
Antimicrob. Agents Chemother. 2005;49:3474-3482.
ABSTRACT | FULL TEXT  

Structural analysis of an HIV-1 protease I47A mutant resistant to the protease inhibitor lopinavir
Kagan et al.
Protein Sci. 2005;14:1870-1878.
ABSTRACT | FULL TEXT  

Immunopathogenesis of Oropharyngeal Candidiasis in Human Immunodeficiency Virus Infection
de Repentigny et al.
Clin. Microbiol. Rev. 2004;17:729-759.
ABSTRACT | FULL TEXT  

Human Immunodeficiency Virus Type 1 Protease Inhibitors Block Toll-Like Receptor 2 (TLR2)- and TLR4-Induced NF-{kappa}B Activation
Equils et al.
Antimicrob. Agents Chemother. 2004;48:3905-3911.
ABSTRACT | FULL TEXT  

Is There an Epidemic of HIV Infection in the US ESRD Program?
Eggers and Kimmel
J. Am. Soc. Nephrol. 2004;15:2477-2485.
ABSTRACT | FULL TEXT  

Highly Active Antiretroviral Therapy and Sexual Risk Behavior: A Meta-analytic Review
Crepaz et al.
JAMA 2004;292:224-236.
ABSTRACT | FULL TEXT  

HIV protease inhibitor ritonavir decreases endothelium-dependent vasorelaxation and increases superoxide in porcine arteries
Conklin et al.
Cardiovasc Res 2004;63:168-175.
ABSTRACT | FULL TEXT  

Enfuvirtide: A Novel Agent for the Treatment of HIV-1 Infection
Duffalo and James
The Annals of Pharmacotherapy 2003;37:1448-1456.
ABSTRACT | FULL TEXT  

Nelfinavir Pharmacokinetics in Stable Human Immunodeficiency Virus-Positive Children: Pediatric AIDS Clinical Trials Group Protocol 377
Floren et al.
Pediatrics 2003;112:e220-227.
ABSTRACT | FULL TEXT  

Psychological Distress is Associated With Decreased Memory Helper T-cell and B-cell Counts in Pre-AIDS HIV Seropositive Men and Women but Only in Those With Low Viral Load
Motivala et al.
Psychosom. Med. 2003;65:627-635.
ABSTRACT | FULL TEXT  

HIV protease inhibitors: antiretroviral agents with anti-inflammatory, anti-angiogenic and anti-tumour activity
Monini et al.
J Antimicrob Chemother 2003;51:207-211.
FULL TEXT  

Predictors of Psychological Well-Being in a Diverse Sample of HIV-Positive Patients Receiving Highly Active Antiretroviral Therapy
Safren et al.
Psychosomatics 2002;43:478-485.
ABSTRACT | FULL TEXT  

HIV Protease Inhibitor Ritonavir Induces Cytotoxicity of Human Endothelial Cells
Zhong et al.
Arterioscler. Thromb. Vasc. Bio. 2002;22:1560-1566.
ABSTRACT | FULL TEXT  

Risk Factors for Urological Symptoms in a Cohort of Users of the HIV Protease Inhibitor Indinavir Sulfate: The ATHENA Cohort
Dieleman et al.
Arch Intern Med 2002;162:1493-1501.
ABSTRACT | FULL TEXT  

Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma
Pati et al.
Blood 2002;99:3771-3779.
ABSTRACT | FULL TEXT  

Highly active antiretroviral treatment does not increase sexual risk behaviour among French HIV infected injecting drug users
Bouhnik et al.
J. Epidemiol. Community Health 2002;56:349-353.
ABSTRACT | FULL TEXT  

Pharmacokinetic Modeling and Simulations of Interaction of Amprenavir and Ritonavir
Sale et al.
Antimicrob. Agents Chemother. 2002;46:746-754.
ABSTRACT | FULL TEXT  

Health and Federal Budgetary Effects of Increasing Access to Antiretroviral Medications for HIV by Expanding Medicaid
Kahn et al.
Am. J. Public Health 2001;91:1464-1473.
ABSTRACT | FULL TEXT  

HIV-Associated Non-Hodgkin Lymphoma: Incidence, Presentation, and Prognosis
Little et al.
JAMA 2001;285:1880-1885.
ABSTRACT | FULL TEXT  

In Vitro Evolution of the Human Immunodeficiency Virus Type 1 Gag-Protease Region and Maintenance of Reverse Transcriptase Resistance following Prolonged Drug Exposure
La Seta Catamancio et al.
J. Clin. Microbiol. 2001;39:1124-1129.
ABSTRACT | FULL TEXT  

Sources Influencing Patients in Their HIV Medication Decisions
Meredith et al.
Health Educ Behav 2001;28:40-50.
ABSTRACT  

Dealing with AIDS-related loss and grief in a time of treatment advances
Demmer
AM J HOSP PALLIAT CARE 2001;18:35-41.
ABSTRACT  

Positive and Negative Aspects of the Human Immunodeficiency Virus Protease: Development of Inhibitors versus Its Role in AIDS Pathogenesis
Ikuta et al.
Microbiol. Mol. Biol. Rev. 2000;64:725-745.
ABSTRACT | FULL TEXT  

HIV-1 protease inhibitors decrease proliferation and induce differentiation of human myelocytic leukemia cells
Ikezoe et al.
Blood 2000;96:3553-3559.
ABSTRACT | FULL TEXT  

Impact of Protease Inhibitors and Other Antiretroviral Treatments on Acquired Immunodeficiency Syndrome Survival in San Francisco, California, 1987-1996
Schwarcz et al.
Am J Epidemiol 2000;152:178-185.
ABSTRACT | FULL TEXT  

A Population Pharmacokinetic Analysis of Nelfinavir Mesylate in Human Immunodeficiency Virus-Infected Patients Enrolled in a Phase III Clinical Trial
Jackson et al.
Antimicrob. Agents Chemother. 2000;44:1832-1837.
ABSTRACT | FULL TEXT  

Highly Active Antiretroviral Therapy for Patients with AIDS Dementia Complex: Effect on MR Imaging Findings and Clinical Course
Thurnher et al.
Am. J. Neuroradiol. 2000;21:670-678.
ABSTRACT | FULL TEXT  

Monitoring patients with HIV disease
Helbert and Breuer
J. Clin. Pathol. 2000;53:266-272.
FULL TEXT  

Perspectives for the Treatment of Infections with Flaviviridae
Leyssen et al.
Clin. Microbiol. Rev. 2000;13:67-82.
ABSTRACT | FULL TEXT  

Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in Adults
Staszewski et al.
NEJM 1999;341:1865-1873.
ABSTRACT | FULL TEXT  

How an Inhibitor of the HIV-I Protease Modulates Proteasome Activity
Schmidtke et al.
J. Biol. Chem. 1999;274:35734-35740.
ABSTRACT | FULL TEXT  

Kinetics of Antiviral Activity and Intracellular Pharmacokinetics of Human Immunodeficiency Virus Type 1 Protease Inhibitors in Tissue Culture
Nascimbeni et al.
Antimicrob. Agents Chemother. 1999;43:2629-2634.
ABSTRACT | FULL TEXT  

Life-Threatening Interactions Between HIV-1 Protease Inhibitors and the Illicit Drugs MDMA and {gamma}-Hydroxybutyrate
Harrington et al.
Arch Intern Med 1999;159:2221-2224.
ABSTRACT | FULL TEXT  

Inhibition of Human Immunodeficiency Virus Type 1 Replication in Acutely and Chronically Infected Cells by EM2487, a Novel Substance Produced by a Streptomyces Species
Baba et al.
Antimicrob. Agents Chemother. 1999;43:2350-2355.
ABSTRACT | FULL TEXT  

Efficacy of Antiretroviral Agents against Murine Replication-Competent Retrovirus Infection in Human Cells
Powell et al.
J. Virol. 1999;73:8813-8816.
ABSTRACT | FULL TEXT  

Antiretroviral-Drug Concentrations in Semen: Implications for Sexual Transmission of Human Immunodeficiency Virus Type 1
Kashuba et al.
Antimicrob. Agents Chemother. 1999;43:1817-1826.
FULL TEXT  

Effects of the Human Immunodeficiency Virus (HIV) Proteinase Inhibitors Saquinavir and Indinavir on In Vitro Activities of Secreted Aspartyl Proteinases of Candida albicans Isolates from HIV-Infected Patients
Korting et al.
Antimicrob. Agents Chemother. 1999;43:2038-2042.
ABSTRACT | FULL TEXT  

Highly Active Antiretroviral Therapy in a Large Urban Clinic: Risk Factors for Virologic Failure and Adverse Drug Reactions
Lucas et al.
ANN INTERN MED 1999;131:81-87.
ABSTRACT | FULL TEXT  

Safety and Pharmacokinetics of Amprenavir (141W94), a Human Immunodeficiency Virus (HIV) Type 1 Protease Inhibitor, following Oral Administration of Single Doses to HIV-Infected Adults
Sadler et al.
Antimicrob. Agents Chemother. 1999;43:1686-1692.
ABSTRACT | FULL TEXT  

Endocrine and Metabolic Evaluation of Human Immunodeficiency Virus-Infected Patients with Evidence of Protease Inhibitor-Associated Lipodystrophy
Yanovski et al.
J. Clin. Endocrinol. Metab. 1999;84:1925-1931.
ABSTRACT | FULL TEXT  

Clinical Progress and the Future of HIV Exceptionalism
Bayer
Arch Intern Med 1999;159:1042-1048.
ABSTRACT | FULL TEXT  

A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity
Baba et al.
Proc. Natl. Acad. Sci. USA 1999;96:5698-5703.
ABSTRACT | FULL TEXT  

Pharmacokinetics of beta -L-2',3'-Dideoxy-5-Fluorocytidine in Rhesus Monkeys
Martin et al.
Antimicrob. Agents Chemother. 1999;43:920-924.
ABSTRACT | FULL TEXT  

Effects of Human Immunodeficiency Virus Type 1 Resistance to Protease Inhibitors on Reverse Transcriptase Processing, Activity, and Drug Sensitivity
de la Carrière et al.
J. Virol. 1999;73:3455-3459.
ABSTRACT | FULL TEXT  

An Analysis of Optimal Resource Allocation for Prevention of Infection with Human Immunodeficiency Virus (HIV) in Injection Drug Users and Non-Users
Richter et al.
Med Decis Making 1999;19:167-179.
ABSTRACT  

Inhibition of Human Immunodeficiency Virus Type 1 Replication by Combination of Transcription Inhibitor K-12 and Other Antiretroviral Agents in Acutely and Chronically Infected Cells
Okamoto et al.
Antimicrob. Agents Chemother. 1999;43:492-497.
ABSTRACT | FULL TEXT  

Mixed Cryoglobulinemia in HIV-1 Infection: The Role of HIV-1
Dimitrakopoulos et al.
ANN INTERN MED 1999;130:226-230.
ABSTRACT | FULL TEXT  

Population Pharmacokinetics of Nevirapine, Zidovudine, and Didanosine in Human Immunodeficiency Virus-Infected Patients
Zhou et al.
Antimicrob. Agents Chemother. 1999;43:121-128.
ABSTRACT | FULL TEXT  

Constrained Evolution of Human Immunodeficiency Virus Type 1 Protease during Sequential Therapy with Two Distinct Protease Inhibitors
Dulioust et al.
J. Virol. 1999;73:850-854.
ABSTRACT | FULL TEXT  

Sino-orbital Aspergillosis in Acquired Immunodeficiency Syndrome
Johnson et al.
Arch Ophthalmol 1999;117:57-64.
ABSTRACT | FULL TEXT  

An Escherichia coli Expression Assay and Screen for Human Immunodeficiency Virus Protease Variants with Decreased Susceptibility to Indinavir
Melnick et al.
Antimicrob. Agents Chemother. 1998;42:3256-3265.
ABSTRACT | FULL TEXT  

Pharmacokinetic Interaction between Ritonavir and Indinavir in Healthy Volunteers
Hsu et al.
Antimicrob. Agents Chemother. 1998;42:2784-2791.
ABSTRACT | FULL TEXT  

Protease Inhibitors as Antiviral Agents
Patick and Potts
Clin. Microbiol. Rev. 1998;11:614-627.
ABSTRACT | FULL TEXT  

The Effects of Protease Inhibitors on the Spread of HIV and the Development of Drug-Resistant HIV Strains: A Simulation Study
Zaric et al.
SIMULATION 1998;71:262-275.
ABSTRACT  

New developments in the biology and treatment of HIV
Bushman et al.
Proc. Natl. Acad. Sci. USA 1998;95:11041-11042.
FULL TEXT  

Self-reported Antiretroviral Therapy in Injection Drug Users
Celentano et al.
JAMA 1998;280:544-546.
ABSTRACT | FULL TEXT  

Sexual Transmission of an HIV-1 Variant Resistant to Multiple Reverse-Transcriptase and Protease Inhibitors
Hecht et al.
NEJM 1998;339:307-311.
FULL TEXT  

Analysis of Ritonavir for the Treatment of HIV Disease in Children: Abstract and Commentary
Oleske
JAMA 1998;279:1831-1831.
FULL TEXT  

Human Immunodeficiency Virus Type 1 Protease Genotypes and In Vitro Protease Inhibitor Susceptibilities of Isolates from Individuals Who Were Switched to Other Protease Inhibitors after Long-Term Saquinavir Treatment
Winters et al.
J. Virol. 1998;72:5303-5306.
ABSTRACT | FULL TEXT  

Loss of Viral Fitness Associated with Multiple Gag and Gag-Pol Processing Defects in Human Immunodeficiency Virus Type 1 Variants Selected for Resistance to Protease Inhibitors In Vivo
Zennou et al.
J. Virol. 1998;72:3300-3306.
ABSTRACT | FULL TEXT  

Inhibition of Methadone and Buprenorphine N-Dealkylations by Three HIV-1 Protease Inhibitors
Iribarne et al.
Drug Metab. Dispos. 1998;26:257-260.
ABSTRACT | FULL TEXT  

Are Advances in Treatment Changing Views about High-Risk Sex?
Dilley et al.
NEJM 1997;337:501-502.
FULL TEXT  

Reduction in CD8+ cell noncytotoxic anti-HIV activity in individuals receiving highly active antiretroviral therapy during primary infection
Stranford et al.
Proc. Natl. Acad. Sci. USA 2001;98:597-602.
ABSTRACT | FULL TEXT  

Mechanism of indinavir-induced hyperbilirubinemia
Zucker et al.
Proc. Natl. Acad. Sci. USA 2001;98:12671-12676.
ABSTRACT | FULL TEXT